Simris Announces Positive Results From Study With Nuvisan

About this update from Simris Group Ab Class B

Simris Group AB OMXSTO:SIMRIS_B:ANNOUNCES POSITIVE RESULTS FROM ONGOING ANTIBODY-DRUG CONJUGATE (ADC) STUDY WITH NUVISANSIMRIS-121 TO PROCEED TO NEXT STAGE OF NUVISAN STUDYDOSE-ESCALATION IN-VIVO STUDY TO DETERMINE MTD OF ADC IN MICE

View stock analysis, news, and events for Simris Group Ab Class B